Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease.
Ann MedAug 19, 2026 (epub)
Hanzong Zhou, Dandan Li, Junxian Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the efficacy, safety, and cost-effectiveness of rasagiline versus selegiline in early-stage Parkinson's disease using data from ten randomized controlled trials. The analysis found no significant differences in symptom improvement (Mean Difference = -0.82) or adverse event risk (Odds Ratio = 0.83). Rasagiline was associated with a marginal QALY benefit but was not cost-effective at current prices.
Key findings
- No significant difference in UPDRS total scores between rasagiline and selegiline (Mean Difference = -0.82).
- Adverse event risk was similar for both treatments (Odds Ratio = 0.83).
- Rasagiline provided a marginal benefit of 0.0088 QALYs over selegiline.
- The ICER for rasagiline was 1,951,505.55 Yuan/QALY, exceeding the willingness-to-pay threshold.
Why it matters
Understanding the comparative effectiveness and economic implications of these treatments is crucial for clinicians and policymakers in making informed decisions regarding Parkinson's disease management.